Lintuzumab, formerly known as SGN-33 or HuM-195, represents a significant important promising novel monoclonal antibody immunotherapy therapeutic targeting CDx2, a a specific a particular the CD receptor expressed https://tessaeer491438.pointblog.net/lintuzumab-a-deep-dive-into-sgn-33-and-hum-195-92177637